Supplemental material
Human Vaccines & Immunotherapeutics
Volume 17, 2021 - Issue 3
Research Paper
Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea
, , 
, , &
Eun-Sil Kangb Health Economics and Outcomes Research, Pfizer Ltd, Seoul, Koreahttps://orcid.org/0000-0002-2900-1520View further author information
https://orcid.org/0000-0002-2900-1520View further author information, , Hyun-Jin Kima Medical Affairs, Pfizer Ltd, Seoul, Koreahttps://orcid.org/0000-0002-4530-0483View further author information
https://orcid.org/0000-0002-4530-0483View further author information & Matt Wassermanc Health Economics and Outcomes Research, Pfizer Inc, New York, NY, USACorrespondence[email protected]
https://orcid.org/0000-0003-3300-2742View further author information
https://orcid.org/0000-0003-3300-2742View further author information